Paige

Paige is a pioneering computational pathology company leveraging large-scale foundation models to transform cancer diagnosis and research. The company has achieved significant regulatory milestones, including the first FDA approval for an AI-based pathology product for prostate cancer detection, and offers a suite of AI applications for prostate, breast, gastrointestinal, and pan-cancer analysis. Its business model combines the sale of its diagnostic software to clinical labs with a technology licensing and services arm for biopharma and research institutions. Positioned at the intersection of AI and oncology, Paige aims to address critical bottlenecks in pathology workflows and unlock new insights from tissue-based data.

Proprietary foundation models (e.g., Virchow) for computational pathology, trained on over 1.5 million digitized tissue slides, enabling development of diagnostic AI applications and research tools for biomarker discovery.

Paige competes in the computational pathology space against other AI-focused startups like PathAI and Proscia, as well as large, established diagnostic companies such as Roche (Ventana) and Philips that are integrating AI into their digital pathology systems. Its key differentiators are its early FDA approval, its large-scale proprietary foundation models, and its dual focus on both clinical diagnostics and biopharma R&D services.